CEBP alpha Antibody (EP709Y)

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

CCAAT/enhancer-binding proteins (C/EBP) consist of a family of transcription factors that play an important role in regulating the balance between cell growth & differentiation. The various isoforms of C/EBP (alpha, beta, gamma, delta, epsilon, zeta) exhibit similar DNA-binding specificities and contain a leucine zipper dimerization domain (1). C/EBP alpha (2) can form heterodimers with related protein C/EBP beta and gamma. C/EBP alpha directly interacts with CDK2and CDK4 and arrests cell proliferation by inhibiting these kinases (3). C/EBP alpha has been shown to bind to the promoter and modulate the expression of leptin, a protein that plays an important role in body weight homeostasis (4). C/EBP alpha also has prominent antimitotic activity and may play a role of a tumor suppressor.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 applications: IP, WB.

Showing Publications 1 - 2 of 2.

Publications using NB110-55639	Applications	Species
Bristol JA, Robinson AR, Barlow EA et al. The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol 2010-12-01 [PMID: 20861254]
Bristol JA, Morrison TE, Kenney SC et al. CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter. Mol Immunol 2009-08-01 [PMID: 19523687] (IP, WB)	IP, WB

Array NB110-55639

• CEBP alpha Antibodies
• CEBP alpha ELISA Kit
• CEBP alpha Lysate
• CEBP alpha Proteins